glp-1 employer coverage news october 2025 Approaches to GLP-1 Coverage in Employer Plans
Description
GLP-1 Receptor Agonists In patients with HFpEF and comorbid obesity or type 2 diabetes mellitus, semaglutide has been incorporated into the 2025 JCS/JHFS heart failure guidelines with a Class IIa recommendation (Level of Evidence B), reflecting moderate-quality evidence supporting improvement in symptoms and functional status
Compounded products containing semaglutide There are various ways that compounded semaglutide products may differ from approved products [1] [2] that may contribute to potential medication errors
N Engl J Med (2017) 377:64457
Sjolund K, Sanden G, Hakanson R, Sundler F
